Vusolimogene oderparepvec

iStock, thomas-bethge After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack of consistency. With new safety guidelines for gene editing therapies, the FDA has taken a first step toward fixing both problems. In declining to approve Replimune’s advanced melanoma drug for the second time, the FDA “has not exercised regulatory flexibility to meet patients’ needs,” Sushil Patel, the biotech’s CEO, said in a strongly worded statement hours after the decision came down last Friday. For patient advocates, regulatory flexibility is the pinnacle of regulatory progress. But for regulators and biopharma companies, the question is more nuanced. In Commissioner Marty Makary’s FDA, it’s “become more explicit that regulatory flexibility is appropriate, but not a waiver of rigor,” Rahul Gupta, president of GATC Health and former director of the White House Office of National Drug Control Policy, said during a BioSpace webinar last month. And rigor is something that seems to be in demand on a population level. According to a recent Politico poll , a majority of Americans are in favor of slowing the approval of new drugs to ensure they are properly tested—even if it means delaying access to those therapies for patients who desperately need them. While this runs counter to appeals from the likes of Sen. Ron Johnson (R-WI), the Rare Disease Advocacy, Biotechnology, and Investor Coalition (RDBI) and myriad other patient advocacy groups, it underscores the complexity of the situation. A BioSpace LinkedIn poll delivered a more divided picture. In answer to the question of whether the FDA is striking an appropriate balance between flexibility and rigor, 34% of respondents said the agency is “too inflexible,” while 23% said the FDA is “too flexible.” A further 19% said the agency is striking an appropriate balance, while 24% were unsure. This balancing act between rigor and access was on full display in the bruhaha surrounding the FDA’s first rejection of Replimune’s RP1, which was proposed in combination with Bristol Myers Squibb’s PD-1 inhibitor Opdivo. In its first complete response letter (CRL) regarding the drug, sent last July, the FDA asserted that the numerically higher response in Replimune’s registrational trial “cannot be adequately interpreted due to heterogeneity of the RPL-001-16 trial patient population.” The agency specifically cited prior exposure to different therapies and severity of disease at baseline. In the second rejection letter , published April 10, a different group of reviewers—intended to “maintain objectivity and account for potential bias,” according to the FDA—also cited heterogeneity of the patient population as an issue. Notably, this unwavering viewpoint within the agency diverged from the collective opinion of 22 scientists involved in the design and execution of the Phase 1/2 IGNYTE study. Far from a methodological shortcoming, these experts considered this heterogeneity to be representative of the real-world scenario. Current treatment guidelines, they wrote in an open letter to the FDA published in August 2025, “show multiple treatment pathways in both the adjuvant and advanced disease setting funneling to the point of IGNYTE eligibility.” That such a diverse group of experts disagreed so fervently on a critical factor of the study’s design speaks to just how complicated it can be to develop a new therapy while also ensuring it is as effective as advertised. Predictability please That isn’t to say that the FDA isn’t committed to bringing rare disease drugs to patients. This week, the agency took a step toward balancing safety with rigor when it published new draft guidance for gene editors. The safety guidance is intended to standardize methods for assessing the safety of gene editing therapies in order to bring them to market faster, according to the agency’s April 14 press release . Standardizing methods of safety assessment make it easier for FDA to approve these products—many of which are for rare diseases. Gene editing FDA bolsters bespoke therapy framework with new draft safety guidelines The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies. April 14, 2026 · 2 min read · Gabrielle Masson Read more FDA might do well to provide—or at least further clarify—this type of guidance across the board. Another issue the Replimune decision exposed is a lack of consistency in the agency’s decision-making, according to Peter Pitts, former FDA associate commissioner for external relations and current president and co-founder of the Center for Medicine in the Public Interest. “The central issue is not whether the FDA should apply rigorous standards—it must,” Pitts wrote in RealClearHealth on Tuesday. “Rather, it is whether those standards are being applied consistently, transparently, and in a manner that allows sponsors to design development programs with confidence that regulatory expectations will remain stable over time.” In addition, Pitts wrote, “the reemergence of concerns regarding trial heterogeneity and the absence of randomized controls—issues that were not clearly determinative during earlier stages of review—suggests a continued lack of alignment between the agency’s guidance and its final decision-making.” In my coverage over the past year, I’ve pointed to this phenomenon time and time again—for example, when the FDA’s final (or late-stage) decision-making regarding rare disease candidates from Capricor Therapeutics and uniQure failed to line up with previous guidance. In clinical trials, RP1 generated an overall response rate of around 33% and a complete response rate of 15%, according to Pitts, “outcomes that compare favorably to historical experience with PD-1 monotherapy in this setting.” “When regulatory expectations evolve late in the process or are applied in ways that diverge from established precedent, the result is not greater scientific rigor. It is diminished predictability,” he wrote. Consistency is particularly important when it comes to clinical trial design—it’s the very foundation upon which approvals are built. The challenge? Aspects of trial design can be exceedingly complicated. Last year, the FDA issued guidance indicating support for—and even encouraging—cell and gene therapy developers to use innovative clinical trial designs, including externally-controlled trials. However, “it’s incredibly complex to determine whether an external control is appropriate,” Harpreet Singh, chief medical officer at Precision for Medicine, told BioSpace earlier this month. The final acceptability of an external control—including historical or real-world data—really can’t be determined until the review process is complete,” said Singh, a former division director of Oncology at the FDA. FDA FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external controls—the application of this flexibility appears to be inconsistent. One former regulator says the situation is more nuanced. April 6, 2026 · 6 min read · Heather McKenzie Read more So what’s a sponsor to do? If you accept Singh’s perspective—and she has years of experience both inside the FDA and with clinical trial design—adopting the FDA’s current guidance surrounding external controls would appear to be a dicey proposition. During last month’s BioSpace webinar, which focused on aligning with the FDA on a regulatory pathway to avoid decision day surprises, Gupta acknowledged that “institutional transitions create policy ambiguity, even when the intent is aligned.” The current challenge, he continued, is “translating that FDA daily direction into actual, predictable and operational guidance for sponsors.” I’d like to applaud the FDA on a positive first step with its safety guidance for gene editing therapies—but there’s more work to be done.

一周之内，不到5天的时间，美国生物医药市场同时上演了三幕截然不同的戏码。 Replimune的溶瘤病毒药物RP1第二次被FDA打回，股价崩跌超60%，公司宣告裁员；Gilead以最高50亿美元收购德国ADC公司Tubulis，干净利落；Neurocrine以29亿美元全现金拿下孤儿药公司Soleno，后者股价一周之内涨超56%。 三个故事，三种结局，但背后只有一条逻辑：证据不硬，监管不放行；资产够硬，大药企抢着掏钱；壁垒够硬，孤儿药能卖出真溢价。 01 第二次被拒意味着什么？ 4月9日晚至10日，Replimune披露收到FDA第二封完全回应函（CRL），FDA拒绝批准RP1（vusolimogene oderparepvec）联合nivolumab治疗抗PD-1后进展晚期黑色素瘤的BLA。 注意，这已经是第二次了。 2025年7月，FDA第一次拒绝时，理由清晰：单臂试验的数据，不足以证明真实临床获益。按理说，Replimune有将近一年的时间去解决这个问题。但4月份的二审结果告诉所有人，证据链没有实质改善，FDA依然不认。 Replimune管理层的公开回应措辞激烈，称FDA审评碎片化、前后不一致。但这几乎于事无补。 市场的判断比公司声明更残酷：4月13日早盘，Replimune股价一度跌61%至1.86美元，盘中最低触及1.50美元，年初以来累计跌约75%，多家卖方机构下调评级至减持。公司随后宣布裁员和产能缩减，在公告语境里，这几乎等同于承认：公司已经没有足够的资金独立推进随机对照试验了。 说白了，这第二封CRL不只是一次审评失败，而是FDA对RP1现有注册逻辑的正式否定：单臂试验冲加速批准，这条路变得很难走了。 02 单臂试验的赌局，中国药企也在押 Replimune的问题，在中国并不陌生。 过去几年，国内不少创新药企同样在走单臂试验＋替代终点的路径，押注FDA加速批准。合理使用政策红利本身没问题，是个捷径，但它或多或少掺杂了赌的成分：赌监管容忍度，赌审评官认可未满足需求，赌没有竞争对手在同一时间递交更扎实的随机对照数据。 Replimune的案例在告诉所有人：这场赌局的赔率，正在快速变低。 FDA在肿瘤领域已经多次释放信号，加速批准不是免检通道，而是一份可以被撤销的临时许可。2024年加速批准改革之后，对替代终点能否预测真实临床获益的审查越来越严，转化验证要求越来越具体。 单臂试验、ORR终点、小样本……这些要素单独存在尚可接受，但叠加在一起又遭遇随机对照数据缺失，这个组合在FDA眼中已经越来越难以接受。 对中国创新药企来说，这不是一个人家被拒跟我有什么关系的问题。 很多企业的出海逻辑，恰恰建立在先拿中国批文，再用同样数据敲美国的门。这条路能不能走通，很大程度上取决于临床试验在设计之初，有没有按FDA真实的证据审查标准来，而不是按差不多能过的心理预期来。 监管不是最后一关，是第一关。如果试验设计本身就没有为全球注册留出余量，后续所有的BD谈判、里程碑定价、海外IPO，都是在沙滩上盖楼。 03 Gilead为什么愿意砸50亿买Tubulis？ 理解了监管的严苛，再看这笔喜气洋洋的收购，逻辑就顺了。 Gilead以31.5亿美元现金预付、最高18.5亿美元里程碑付款，合计最高50亿美元，收购德国ADC公司Tubulis，预计于2026年二季度完成。 这家公司的核心价值有两块：一是针对NaPi2b等靶点的临床期ADC管线；二是能显著降低毒性的新一代连接子/载荷平台，收购后将作为Gilead在慕尼黑的专属ADC研发中心独立运营。 大药企买这类资产，不看故事，看三件事：机制是否差异化、毒性窗口是否更优、全球临床注册路径是否清晰。 巧了，Tubulis三样都有。 而且这是Gilead短期内第三笔重磅并购；此前Arcellx偏肿瘤，Ouro偏免疫，Tubulis则进一步补强其ADC肿瘤布局。三笔交易，预计于2026年二季度完成。 密集出手的背后逻辑只有一个：当专利悬崖临近、内生研发无法及时填补，大药企最理性的选择就是去外部买证据足够硬、监管路径足够清晰的资产。买概念，已经过时了。 Tubulis被收购的逻辑，与Replimune被拒的逻辑，是同一枚硬币的两面：监管确定性，是资产能否被高价收购的前提条件。一个过了这道门，一个没过，差距就是几十亿美元。 04 29亿美元买孤儿药，溢价从哪来？ 如果说前两个案例是关于监管能否通过，Neurocrine收购Soleno，则是在教另一课：真正被监管偏爱并筑起壁垒的孤儿药，比任何临床阶段的故事都值钱。 Neurocrine以每股53美元、总对价约29亿美元全现金收购Soleno，较公告前溢价约34%，较30日均价溢价约51%，Soleno股价一周之内累计涨超56%。 核心标的是Vykat XR，美国首个且目前唯一获批用于治疗Prader-Willi综合征相关病理性饥饿的孤儿药。2025年全年收入约1.9亿美元，Q4单季贡献约9200万美元，年化超3.6亿美元，且仍处商业化早期。 孤儿药的核心竞争力，从来不在规模，在于：无集采压力、无大规模仿制竞争、患者终身用药、定价权长期稳固。Neurocrine买的不是增长故事，而是一个可预期的、高质量的现金流。 这对中国VC和大药企的战略并购有直接参考价值。 过去几年，国内投资逻辑主要围绕“大赛道、大市场、高峰值销售”，孤儿病和小众适应症的商业价值是被看到的，但资产的估值框架怎么具象定义，相对不够完全成熟。但现实是，在监管门槛持续抬高、临床成本持续上升的当下，已上市、有定价权、在小赛道做到唯一或第一的资产，往往比大而全但未商业化的管线更容易在并购中获得真实溢价。 更深一层：孤儿药能获得监管快速通道、市场独占期保护，这本身也是监管逻辑给予的确定性。最终兑现的溢价，还是要回归到监管这个原点。 05 这笔账，中国药企和投资人该怎么算？ 2026年一季度，中国创新药对外授权交易总额超过600亿美元，热度居历史高位。但热闹背后，那些真正被海外大药企付真钱接走的项目，无一例外都是监管路径清晰的；那些被低价打包甚至无人问津的，往往是临床设计早期就埋下了监管隐患。 这就是2026年创新药市场真正的竞争维度。 不是谁的故事讲得更宏大，不是谁的靶点更新颖，而是，你这套临床证据，FDA、EMA和NMPA都能接受吗？ Replimune给出了最昂贵的反面教材：一款机制上有独特性的溶瘤病毒药物，因为试验设计上的路径依赖和证据不足，最终被监管拦在门外，市值断崖，公司裁员求生。而Gilead买Tubulis、Neurocrine买Soleno，不过是在用真金白银确认同一件事：监管的确定性和监管直接筑起壁垒，才是最稀缺的溢价来源。 这一点，这个月的美国市场已经用真金白银说清楚了。 本文来自微信公众号“分子稳态”，作者：创新药组 稳态君，36氪经授权发布。